Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.38 |
| ▸ | RAB9A | P51151 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83810 | 0.81 | KDM4E (0.41) | NPC1KMT2ARAB9AMEN1ALDH1A1 | |
| SCHEMBL5574433 | 0.77 | ALDH1A1 (0.48) | NPC1KMT2ARAB9AMEN1ALDH1A1 | |
| SCHEMBL7560764 | 0.71 | — | — | |
| SCHEMBL30523 | 0.71 | TRIM24 (0.45) | NPC1KMT2ARAB9AMEN1ALDH1A1 | |
| SCHEMBL2813908 | 0.69 | NPC1 (0.38) | NPC1KMT2ARAB9AMEN1ALDH1A1 | |
| SCHEMBL28143450 | 0.69 | — | — | |
| SCHEMBL10979619 | 0.69 | — | — | |
| SCHEMBL1655684 | 0.68 | ALOX5 (0.39) | NPC1KMT2ARAB9AMEN1ALDH1A1 | |
| SCHEMBL1381419 | 0.68 | POLB (0.46) | NPC1KMT2ARAB9AMEN1ALDH1A1 | |
| Bromide SCHEMBL12482879 | 0.68 | NPC1 (0.37) | NPC1KMT2ARAB9AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2527340-B1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-08-17 | — | — | EP | disclosed |
| EP-2407466-B1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-9062035-B2 | Piperazine compound capable of inhibiting prostaglandin D synthase | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-8865714-B2 | Piperazine compound capable of inhibiting prostaglandin D synthase | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| US-8765750-B2 | Piperazine compound having a PGDS inhibitory effect | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140128394-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-05-08 | — | — | US | disclosed |
| US-20120309760-A1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-2407466-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | Taiho Pharmaceutical Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319413-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128394-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | PTGDR, PTGS1, PTGDR2 | NPC1 1761/4885KMT2A 3441/4885RAB9A 2924/4885 |
| US-20120309760-A1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | GRIK5, GRK5, KCNJ5 | NPC1 2196/4885KMT2A 4777/4885RAB9A 2908/4885 |
| US-20110319413-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | PTGS1, PTGDR, PTGIS | NPC1 2418/4885KMT2A 4129/4885RAB9A 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.